Co-Diagnostics (NASDAQ:CODX) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Valuation & Earnings
This table compares Co-Diagnostics and Apyx Medical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apyx Medical||$16.69 million||14.84||$64.01 million||($0.29)||-25.17|
Apyx Medical has higher revenue and earnings than Co-Diagnostics.
This is a summary of recent ratings and target prices for Co-Diagnostics and Apyx Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Co-Diagnostics currently has a consensus target price of $2.00, suggesting a potential upside of 78.57%. Apyx Medical has a consensus target price of $8.00, suggesting a potential upside of 9.59%. Given Co-Diagnostics’ higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Apyx Medical.
This table compares Co-Diagnostics and Apyx Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
10.6% of Co-Diagnostics shares are held by institutional investors. Comparatively, 46.0% of Apyx Medical shares are held by institutional investors. 6.0% of Apyx Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Apyx Medical beats Co-Diagnostics on 8 of the 10 factors compared between the two stocks.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Apyx Medical Company Profile
Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.